<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Pulse Biosciences, Inc — News on 6ix</title>
<link>https://6ix.com/company/pulse-biosciences-inc</link>
<description>Latest news and press releases for Pulse Biosciences, Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 12 May 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/pulse-biosciences-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835ae2678dffbe2df10eb76.webp</url>
<title>Pulse Biosciences, Inc</title>
<link>https://6ix.com/company/pulse-biosciences-inc</link>
</image>
<item>
<title>ATM Equity Purchases by Pulse Biosciences’ Co-Chairmen Total Approximately $13.3 Million</title>
<link>https://6ix.com/company/pulse-biosciences-inc/news/atm-equity-purchases-by-pulse-biosciences-co-chairmen-total-approximately-dollar133-million</link>
<guid isPermaLink="true">https://6ix.com/company/pulse-biosciences-inc/news/atm-equity-purchases-by-pulse-biosciences-co-chairmen-total-approximately-dollar133-million</guid>
<pubDate>Tue, 12 May 2026 11:00:00 GMT</pubDate>
<description>HAYWARD, Calif., May 12, 2026--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced its Co-Chairmen of the Board, Robert Duggan and Chief Executive Officer Paul LaViolette, completed purchases of Pulse Biosciences’ common stock through its at-the-market equity offering program (ATM) during the Company’s designated trading window.</description>
</item>
<item>
<title>Pulse Biosciences to Present at the BofA Securities 2026 Healthcare Conference</title>
<link>https://6ix.com/company/pulse-biosciences-inc/news/pulse-biosciences-to-present-at-the-bofa-securities-2026-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/pulse-biosciences-inc/news/pulse-biosciences-to-present-at-the-bofa-securities-2026-healthcare-conference</guid>
<pubDate>Fri, 08 May 2026 11:00:00 GMT</pubDate>
<description>HAYWARD, Calif., May 08, 2026--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced plans to participate in the upcoming BofA Securities 2026 Healthcare Conference in Las Vegas, NV.</description>
</item>
<item>
<title>Turbett Surgical Appoints Kevin Danahy as President and Chief Executive Officer to Lead Growth Phase</title>
<link>https://6ix.com/company/pulse-biosciences-inc/news/turbett-surgical-appoints-kevin-danahy-as-president-and-chief-executive-officer-to-lead-growth-phase</link>
<guid isPermaLink="true">https://6ix.com/company/pulse-biosciences-inc/news/turbett-surgical-appoints-kevin-danahy-as-president-and-chief-executive-officer-to-lead-growth-phase</guid>
<pubDate>Wed, 06 May 2026 12:00:00 GMT</pubDate>
<description>ROCHESTER, N.Y., May 06, 2026--Turbett Surgical is proud to announce the appointment of Kevin Danahy as President and Chief Executive Officer. A visionary leader known for his "founder-mentality," Danahy joins the company with a mandate to instill a high-performance culture and lead the organization through its next era of clinical expansion and commercial excellence.</description>
</item>
<item>
<title>Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results</title>
<link>https://6ix.com/company/pulse-biosciences-inc/news/pulse-biosciences-reports-business-updates-and-first-quarter-2026-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/pulse-biosciences-inc/news/pulse-biosciences-reports-business-updates-and-first-quarter-2026-financial-results</guid>
<pubDate>Mon, 04 May 2026 11:00:00 GMT</pubDate>
<description>HAYWARD, Calif., May 04, 2026--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced business updates and financial results for the first quarter ended March 31, 2026.</description>
</item>
<item>
<title>Pulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulse™ Cardiac Catheter System at Heart Rhythm 2026</title>
<link>https://6ix.com/company/pulse-biosciences-inc/news/pulse-biosciences-presents-positive-outcomes-in-late-breaking-updated-data-from-npulsetm-cardiac-catheter-system-at-heart-rhythm-2026</link>
<guid isPermaLink="true">https://6ix.com/company/pulse-biosciences-inc/news/pulse-biosciences-presents-positive-outcomes-in-late-breaking-updated-data-from-npulsetm-cardiac-catheter-system-at-heart-rhythm-2026</guid>
<pubDate>Sat, 25 Apr 2026 17:00:00 GMT</pubDate>
<description>HAYWARD, Calif., April 25, 2026--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced late-breaking positive clinical data from its nPulse Cardiac Catheter System first-in-human feasibility study at the Heart Rhythm 2026 meeting.</description>
</item>
<item>
<title>Pulse Biosciences’ nPulse™ Technology to be Featured at the Heart Rhythm Society 2026 Annual Meeting</title>
<link>https://6ix.com/company/pulse-biosciences-inc/news/pulse-biosciences-npulsetm-technology-to-be-featured-at-the-heart-rhythm-society-2026-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/pulse-biosciences-inc/news/pulse-biosciences-npulsetm-technology-to-be-featured-at-the-heart-rhythm-society-2026-annual-meeting</guid>
<pubDate>Mon, 20 Apr 2026 11:00:00 GMT</pubDate>
<description>HAYWARD, Calif., April 20, 2026--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation™ (nsPFA™) energy, today announced that its nPulse™ Cardiac Catheter will be prominently featured during the Heart Rhythm Society (HRS) 2026 Annual Meeting, taking place April 23-26 in Chicago, Illinois.</description>
</item>
<item>
<title>Pulse Biosciences to Host Analyst Event on April 25, 2026</title>
<link>https://6ix.com/company/pulse-biosciences-inc/news/pulse-biosciences-to-host-analyst-event-on-april-25-2026</link>
<guid isPermaLink="true">https://6ix.com/company/pulse-biosciences-inc/news/pulse-biosciences-to-host-analyst-event-on-april-25-2026</guid>
<pubDate>Fri, 17 Apr 2026 11:00:00 GMT</pubDate>
<description>HAYWARD, Calif., April 17, 2026--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced plans to host an analyst event following the presentation of its late-breaking data at the Heart Rhythm Society on April 25, 2026, in Chicago, Illinois.</description>
</item>
<item>
<title>Pulse Biosciences Strengthens Executive Leadership Team</title>
<link>https://6ix.com/company/pulse-biosciences-inc/news/pulse-biosciences-strengthens-executive-leadership-team</link>
<guid isPermaLink="true">https://6ix.com/company/pulse-biosciences-inc/news/pulse-biosciences-strengthens-executive-leadership-team</guid>
<pubDate>Thu, 09 Apr 2026 04:00:00 GMT</pubDate>
<description>Appoints Liane Teplitsky as Chief Operating Officer Expands Dr. David Kenigsberg’s Chief Medical Officer Role HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse</description>
</item>
<item>
<title>Pulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation</title>
<link>https://6ix.com/company/pulse-biosciences-inc/news/pulse-biosciences-enrolls-first-patients-in-nanopulse-af-ide-pivotal-clinical-study-evaluating-npulsetm-cardiac-catheter-system-for-atrial-fibrillation</link>
<guid isPermaLink="true">https://6ix.com/company/pulse-biosciences-inc/news/pulse-biosciences-enrolls-first-patients-in-nanopulse-af-ide-pivotal-clinical-study-evaluating-npulsetm-cardiac-catheter-system-for-atrial-fibrillation</guid>
<pubDate>Tue, 07 Apr 2026 04:00:00 GMT</pubDate>
<description>U.S. IDE Enrollment follows groundbreaking 96% procedural success at 12 months in European feasibility study HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse</description>
</item>
<item>
<title>Pulse Biosciences to Present at the 25th Annual Needham Virtual Healthcare Conference</title>
<link>https://6ix.com/company/pulse-biosciences-inc/news/pulse-biosciences-to-present-at-the-25th-annual-needham-virtual-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/pulse-biosciences-inc/news/pulse-biosciences-to-present-at-the-25th-annual-needham-virtual-healthcare-conference</guid>
<pubDate>Thu, 02 Apr 2026 20:05:00 GMT</pubDate>
<description>HAYWARD, Calif., April 02, 2026--Pulse Biosciences, Inc. (Nasdaq: PLSE), pioneer of the novel nPulse™ platform using proprietary Nanosecond Pulsed Field Ablation (nsPFA™), today announced plans to present at the upcoming 25th Annual Needham Virtual Healthcare Conference.</description>
</item>
<item>
<title>Pulse Biosciences Announces Strategic Alignment to Accelerate Cardiac Catheter Program Following Exceptional Long-Term AFib Clinical Data</title>
<link>https://6ix.com/company/pulse-biosciences-inc/news/pulse-biosciences-announces-strategic-alignment-to-accelerate-cardiac-catheter-program-following-exceptional-long-term-afib-clinical-data</link>
<guid isPermaLink="true">https://6ix.com/company/pulse-biosciences-inc/news/pulse-biosciences-announces-strategic-alignment-to-accelerate-cardiac-catheter-program-following-exceptional-long-term-afib-clinical-data</guid>
<pubDate>Tue, 17 Mar 2026 04:00:00 GMT</pubDate>
<description>HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE), pioneer of the novel nPulse™ platform using proprietary Nanosecond Pulsed Field</description>
</item>
<item>
<title>Pulse Biosciences, Inc. Announces First Enrollments in Feasibility Study for the Treatment of Malignant Thyroid Tumors with nPulse™ Technology</title>
<link>https://6ix.com/company/pulse-biosciences-inc/news/pulse-biosciences-inc-announces-first-enrollments-in-feasibility-study-for-the-treatment-of-malignant-thyroid-tumors-with-npulsetm-technology-5</link>
<guid isPermaLink="true">https://6ix.com/company/pulse-biosciences-inc/news/pulse-biosciences-inc-announces-first-enrollments-in-feasibility-study-for-the-treatment-of-malignant-thyroid-tumors-with-npulsetm-technology-5</guid>
<pubDate>Thu, 12 Mar 2026 04:00:00 GMT</pubDate>
<description>HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using its proprietary Nanosecond Pulsed</description>
</item>
<item>
<title>Pulse Biosciences Announces Clinical Data From nPulse™ Vybrance™ System First-In-Human Clinical Durability Study of Benign Thyroid Nodule Ablation</title>
<link>https://6ix.com/company/pulse-biosciences-inc/news/pulse-biosciences-announces-clinical-data-from-npulsetm-vybrancetm-system-first-in-human-clinical-durability-study-of-benign-thyroid-nodule-ablation</link>
<guid isPermaLink="true">https://6ix.com/company/pulse-biosciences-inc/news/pulse-biosciences-announces-clinical-data-from-npulsetm-vybrancetm-system-first-in-human-clinical-durability-study-of-benign-thyroid-nodule-ablation</guid>
<pubDate>Mon, 09 Mar 2026 04:00:00 GMT</pubDate>
<description>Durable volume reduction was demonstrated with an average volume reduction of 74% of treated benign thyroid nodules at 15-22 months post-treatment. HAYWARD,</description>
</item>
<item>
<title>Pulse Biosciences to Present at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference</title>
<link>https://6ix.com/company/pulse-biosciences-inc/news/pulse-biosciences-to-present-at-the-oppenheimer-36th-annual-healthcare-medtech-and-services-conference-5</link>
<guid isPermaLink="true">https://6ix.com/company/pulse-biosciences-inc/news/pulse-biosciences-to-present-at-the-oppenheimer-36th-annual-healthcare-medtech-and-services-conference-5</guid>
<pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
<description>HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using its proprietary Nanosecond Pulsed</description>
</item>
<item>
<title>Pulse Biosciences’ nPulse™ Vybrance™ System to be Featured in Multiple Presentations at the North American Society for Interventional Thyroidology Meeting</title>
<link>https://6ix.com/company/pulse-biosciences-inc/news/pulse-biosciences-npulsetm-vybrancetm-system-to-be-featured-in-multiple-presentations-at-the-north-american-society-for-interventional-thyroidology-meeting-6</link>
<guid isPermaLink="true">https://6ix.com/company/pulse-biosciences-inc/news/pulse-biosciences-npulsetm-vybrancetm-system-to-be-featured-in-multiple-presentations-at-the-north-american-society-for-interventional-thyroidology-meeting-6</guid>
<pubDate>Wed, 04 Mar 2026 05:00:00 GMT</pubDate>
<description>nPulse™ Vybrance™ System for soft tissue ablation, such as benign thyroid ablation, to be highlighted in podium presentation and product theatre presentation</description>
</item>
<item>
<title>Pulse Biosciences to Present at the 46th Annual TD Cowen Healthcare Conference</title>
<link>https://6ix.com/company/pulse-biosciences-inc/news/pulse-biosciences-to-present-at-the-46th-annual-td-cowen-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/pulse-biosciences-inc/news/pulse-biosciences-to-present-at-the-46th-annual-td-cowen-healthcare-conference</guid>
<pubDate>Fri, 20 Feb 2026 12:00:00 GMT</pubDate>
<description>HAYWARD, Calif., February 20, 2026--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced plans to present at the upcoming 46th Annual TD Cowen Healthcare Conference in Boston.</description>
</item>
<item>
<title>Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/pulse-biosciences-inc/news/pulse-biosciences-reports-business-updates-and-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/pulse-biosciences-inc/news/pulse-biosciences-reports-business-updates-and-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Thu, 19 Feb 2026 21:05:00 GMT</pubDate>
<description>HAYWARD, Calif., February 19, 2026--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced business updates and financial results for the fourth quarter and full year ended December 31, 2025.</description>
</item>
<item>
<title>Pulse Biosciences Presents Late-Breaking Data from nPulse™ Cardiac Catheter System First-In-Human Feasibility Study at the AF Symposium</title>
<link>https://6ix.com/company/pulse-biosciences-inc/news/pulse-biosciences-presents-late-breaking-data-npulsetm-cardiac-catheter-system-first</link>
<guid isPermaLink="true">https://6ix.com/company/pulse-biosciences-inc/news/pulse-biosciences-presents-late-breaking-data-npulsetm-cardiac-catheter-system-first</guid>
<pubDate>Thu, 05 Feb 2026 05:00:00 GMT</pubDate>
<description>Procedural success was achieved in 100% of evaluable patients at 6 months and 96% in 12 months HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc.</description>
</item>
<item>
<title>Pulse Biosciences Schedules Fourth Quarter & Full Year 2025 Financial Results Conference Call for February 19, 2026</title>
<link>https://6ix.com/company/pulse-biosciences-inc/news/pulse-biosciences-schedules-fourth-quarter-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/pulse-biosciences-inc/news/pulse-biosciences-schedules-fourth-quarter-full-year-2025-financial-results</guid>
<pubDate>Wed, 04 Feb 2026 05:00:00 GMT</pubDate>
<description>HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond</description>
</item>
<item>
<title>Pulse Biosciences’ nPulse™ Cardiac Catheter to Be Featured in Multiple Presentations at the AF Symposium</title>
<link>https://6ix.com/company/pulse-biosciences-inc/news/pulse-biosciences-npulsetm-cardiac-catheter-be-featured-multiple-presentations-af</link>
<guid isPermaLink="true">https://6ix.com/company/pulse-biosciences-inc/news/pulse-biosciences-npulsetm-cardiac-catheter-be-featured-multiple-presentations-af</guid>
<pubDate>Tue, 03 Feb 2026 05:00:00 GMT</pubDate>
<description>nPulse Cardiac Catheter for AF ablation to be highlighted in late-breaking clinical science session and in a live case transmission HAYWARD,</description>
</item>
</channel>
</rss>